ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BCRX vs VIR // OPERATING MARGIN

BioCryst Pharmaceuticals Inc. (NASDAQ) VS. Vir Biotechnology Inc. (NASDAQ) • 15-METRIC TALLY: BCRX 5 — VIR 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCRX VS. VIR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BCRX VIR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 96.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -35.00% +120.00 BCRX /roic <GO>
EV/EBITDA & P/E Valuation 6.1x — — TIE /valuation <GO>
Free Cash Flow Yield 15.96% -19.74% +35.70 BCRX /fcf-yield <GO>
Operating Margin ACTIVE — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -7.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 2.40 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 4/9 +2.00 BCRX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.8 53.8 +0.99 BCRX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 7.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.18B $2.01B $168.1M BCRX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BCRX REV VIR REV BCRX GROSS % VIR GROSS % BCRX FCF VIR FCF
FY 2025 $0 $68.6M — 98.0% $347.4M -$396.6M
FY 2024 $0 $74.2M — 98.0% -$52.0M -$453.7M
FY 2023 $0 $86.2M — — -$95.1M -$778.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCRX // BETA —
VIR // BETA —